Characterization of the Photodegradation of a Human IgG1 Monoclonal Antibody Formulated as a High-Concentration Liquid Dosage Form

被引:98
|
作者
Qi, Pei [1 ]
Volkin, David B. [1 ]
Zhao, Hui [1 ]
Nedved, Michael L. [1 ]
Hughes, Robert [1 ]
Bass, Ryan [1 ]
Yi, Sun C. [1 ]
Panek, Mark E. [1 ]
Wang, Dana [1 ]
Dalmonte, Paul [1 ]
Bond, Michael D. [1 ]
机构
[1] Centocor R&D Inc, Pharmaceut Dev Dept, Radnor, PA 19087 USA
关键词
monoclonal antibody; IgG; photostability; photodegradation; discoloration; liquid formulation; ABSORBING AMINO-ACIDS; SIMPLE DERIVATIVES; TRYPTOPHAN; STABILITY; OXIDATION; PHOTOCHEMISTRY; PHOTOPHYSICS; AGGREGATION; PROTEINS; RESIDUES;
D O I
10.1002/jps.21617
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The photodegradation of a human IgG1 monoclonal antibody has been examined in a high concentration (100 mg/mL) liquid formulation. It was observed that a yellowish color is generated when the formulation is exposed to intense and prolonged light exposure, and this discoloration occurs along with a loss in bioactivity. Extensive analytical characterization was performed to determine light induced degradation pathways that occur during exposure to intense light of ICH photodegradation conditions. It has been shown that the monoclonal antibody undergoes a combination of physical and chemical reactions under these conditions, including covalent aggregate formation, fragmentation at the hinge region, oxidation of Trp, His, and Met residues, and deamidation of Asn residues. Oxidation of Trp 94 and deamidation of Asn 93, located in the light chain CDR region, correlates with loss of bioactivity under these conditions. A series of formulation experiments were performed to elucidate the impact of the extent of light exposure, oxygen, protein concentration, and solution pH on the photostability of the formulation. Results demonstrated that photodegradation of the IgG, after intensive light exposure, can be prevented by proper secondary packaging. In addition, it is also shown that a high concentration, liquid dosage form of a human monoclonal antibody is stable upon exposure to the ambient light conditions encountered during routine manufacturing, long-term storage, and administration with proper design of formulation conditions, the primary container as well as the secondary package. (c) 2008 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 98:3117-3130, 2009
引用
收藏
页码:3117 / 3130
页数:14
相关论文
共 50 条
  • [41] Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody
    Donahue, Renee N.
    Lepone, Lauren M.
    Grenga, Italia
    Jochems, Caroline
    Fantini, Massimo
    Madan, Ravi A.
    Heery, Christopher R.
    Gulley, James L.
    Schlom, Jeffrey
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [42] The mouse monoclonal antibody 4E3 is specific for the G1m17 allotype of human IgG1
    Moverare, Robert
    Lind, Peter
    DeWitt, Asa Marknell
    JOURNAL OF IMMUNOLOGICAL METHODS, 2024, 534
  • [43] Generation and characterization of a novel human IgG1 antibody against vascular endothelial growth factor receptor 2
    Wei Xie
    Daojuan Li
    Juan Zhang
    Zhike Li
    Desmond Omane Acheampong
    Yuan He
    Youfu Wang
    Zhiguo Chen
    Min Wang
    Cancer Immunology, Immunotherapy, 2014, 63 : 877 - 888
  • [44] Generation and characterization of a novel human IgG1 antibody against vascular endothelial growth factor receptor 2
    Xie, Wei
    Li, Daojuan
    Zhang, Juan
    Li, Zhike
    Acheampong, Desmond Omane
    He, Yuan
    Wang, Youfu
    Chen, Zhiguo
    Wang, Min
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2014, 63 (09) : 877 - 888
  • [45] First clinical results of HuMax-CD20 fully human monoclonal IGG1 antibody treatment in rheumatoid arthritis
    Ostergaard, M.
    Wiell, C.
    Dawes, P. T.
    Rigby, W.
    Petersen, J.
    Kastberg, H.
    Sierakowski, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 58 - 59
  • [46] Analysis of post-translational modifications in recombinant monoclonal antibody IgG1 by reversed-phase liquid chromatography/mass spectrometry
    Yan, Boxu
    Valliere-Douglass, John
    Brady, Lowell
    Steen, Sean
    Han, Mei
    Pace, Danielle
    Elliott, Susan
    Yates, Zac
    Han, Yihong
    Balland, Alain
    Wang, Weichun
    Pettit, Dean
    JOURNAL OF CHROMATOGRAPHY A, 2007, 1164 (1-2) : 153 - 161
  • [47] A NOVEL HLA-A DETERMINANT RECOGNIZED BY A CYTOTOXIC HUMAN HYBRIDOMA IGG1 MONOCLONAL-ANTIBODY (TRJ14)
    GE, J
    BRATLIE, A
    HANNESTAD, K
    TISSUE ANTIGENS, 1994, 44 (05): : 306 - 310
  • [48] COMPARISON OF THE OPSONIC AND COMPLEMENT TRIGGERING ACTIVITY OF HUMAN MONOCLONAL IGG1 AND IGM ANTIBODY AGAINST GROUP-B STREPTOCOCCI
    SHYUR, SD
    RAFF, HV
    BOHNSACK, JF
    KELSEY, DK
    HILL, HR
    JOURNAL OF IMMUNOLOGY, 1992, 148 (06): : 1879 - 1884
  • [49] Characterization of glycosylation sites for a recombinant IgG1 monoclonal antibody and a CTLA4-Ig fusion protein by liquid chromatography-mass spectrometry peptide mapping
    Bongers, Jacob
    Devincentis, John
    Fu, Jinmei
    Huang, Peiqing
    Kirkley, David H.
    Leister, Kirk
    Liu, Peiran
    Ludwig, Richard
    Rumney, Kathleen
    Tao, Li
    Wu, Wei
    Russell, Reb J.
    JOURNAL OF CHROMATOGRAPHY A, 2011, 1218 (45) : 8140 - 8149
  • [50] Bacterial production and functional characterization of the Fab fragment of the murine IgG1/λ monoclonal antibody cmHsp70.1, a reagent for tumour diagnostics
    Friedrich, Lars
    Stangl, Stefan
    Hahne, Hannes
    Kuester, Bernhard
    Koehler, Peter
    Multhoff, Gabriele
    Skerra, Arne
    PROTEIN ENGINEERING DESIGN & SELECTION, 2010, 23 (04): : 161 - 168